EGFR and cancer: While less efficient than EGFR-TKIs in inhibiting the growth of EGFR mutant cancer cells, sorafenib and chemotherapy specifically target the emerging subpopulations of resistant cells, thus prolonging NSCLC response to EGFR-TKIs.